medi-cal glp-1 coverage CMS Issues Guidance on Anti-Obesity Drugs 🚨 BIG NEWS FOR MEDICARE

These molecules retain a phloroglucinol scaffold fused to terpenoid moieties, and their hybrid architecture likely supports multiple mechanisms of action, including membrane destabilization and oxidative stress induction

Results confirmed liraglutide's superiority: HbA1c reduction: -1.48% (liraglutide) vs -1.28% (exenatide ER) Weight loss: -3.57 kg (liraglutide) vs -2.68 kg (exenatide ER) Weight Loss Comparison# Exenatide (DURATION Program)# Exenatide was developed for type 2 diabetes, not weight management: DURATION-1: 3.7 kg weight loss with Bydureon over 30 weeks DURATION-5: 2.3 kg weight loss over 24 weeks Three-year extension: 2.3 kg sustained weight reduction No FDA approval for chronic weight management Liraglutide (SCALE Program)# Liraglutide was specifically developed for obesity at the higher 3.0 mg dose: SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015): 8.0% mean weight loss at 56 weeks 63.2% achieved 5% or more weight loss

For patients deciding between semaglutide and tirzepatide or between standard dose and microdose genetic insight can add another layer of personalization

Dekant, W

Alongside BPC-157, the review examined TB-500, GHK-Cu, MOTS-C, CJC-1295, and Ipamorelin

No superar la dosis diaria